EHOC 2022 | Signaling pathways involved in drug resistance in MPNs
Alessandro Lucchesi
• 12 Oct 2022
Alessandro Lucchesi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, shares some insights into signaling pathways involved in drug resistance in myeloproliferative neoplasms (MPNs), drawing focus on the pathways involved in resistance to ruxolitinib. Dr Lucchesi also comments on agents that may be combined with ruxolitinib, including navitoclax and parsaclisib. This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
